Many patients do have input into the choice between lanreotide and octreotide, so it is absolutely reasonable to discuss your preference with the doctor.

Both are standard SSA treatments for Grade 1 small bowel NETs and work very similarly for tumor control and symptom management.

In general:

Lanreotide is a deep subcutaneous injection (under the skin) and many patients find it more convenient.
Octreotide LAR is an intramuscular injection and sometimes requires a longer clinic visit and more preparation.

Some doctors prefer one based on:

Their experience
Insurance coverage
Injection center logistics
Specific symptoms or tumor behavior

But in many cases, patient comfort and convenience are part of the decision.

UCSF NET specialists deal with this all the time, so it would be very reasonable to simply ask:

“Is there any reason lanreotide would not be a good option for him?”

Many patients with slow-growing Grade 1 NETs do very well on SSA therapy for years.